Biotechnology Companies By Ps Ratio
LargestBiggest EarnersMost ProfitableMost LiquidHighly LeveragedTop DividendsCapital-HeavyHighest ValuationLargest Workforce
Price To Sales
| Price To Sales | Efficiency | Market Risk | Exp Return | ||||
|---|---|---|---|---|---|---|---|
| 1 | NKTX | Nkarta Inc | (0.06) | 5.58 | (0.31) | ||
| 2 | SVRA | Savara Inc | (0.07) | 3.27 | (0.22) | ||
| 3 | EDSA | Edesa Biotech | 0.02 | 3.58 | 0.07 | ||
| 4 | TIL | Instil Bio | 0.21 | 15.58 | 3.34 | ||
| 5 | KZIA | Kazia Therapeutics Ltd | 0.12 | 34.37 | 4.00 | ||
| 6 | DSGN | Design Therapeutics | 0.12 | 5.61 | 0.70 | ||
| 7 | CVM | CEL SCI Corp | (0.03) | 4.20 | (0.11) | ||
| 8 | GNLX | Genelux Common | 0.07 | 6.62 | 0.46 | ||
| 9 | RVMD | Revolution Medicines | 0.12 | 2.64 | 0.31 | ||
| 10 | ALLO | Allogene Therapeutics | 0.08 | 5.69 | 0.44 | ||
| 11 | KROS | Keros Therapeutics | 0.20 | 3.08 | 0.63 | ||
| 12 | VRDN | Viridian Therapeutics | 0.22 | 5.33 | 1.15 | ||
| 13 | ALXO | Alx Oncology Holdings | (0.20) | 7.52 | (1.52) | ||
| 14 | LYEL | Lyell Immunopharma | (0.04) | 6.04 | (0.26) | ||
| 15 | PMN | ProMIS Neurosciences | (0.12) | 6.10 | (0.73) | ||
| 16 | CGON | CG Oncology, Common | 0.08 | 3.14 | 0.25 | ||
| 17 | CHHL | China Holdings | 0.00 | 0.00 | 0.00 | ||
| 18 | DNLI | Denali Therapeutics | 0.17 | 3.07 | 0.51 | ||
| 19 | CRNX | Crinetics Pharmaceuticals | 0.11 | 2.58 | 0.28 | ||
| 20 | PLRX | Pliant Therapeutics | 0.04 | 3.44 | 0.15 |
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries. The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.